Skip to main content

Drug Interactions between aprotinin and prothrombin complex

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

aprotinin prothrombin complex

Applies to: aprotinin and prothrombin complex

GENERALLY AVOID: Due to additive or synergistic pharmacodynamic effects, the risk of thrombosis may be increased when antifibrinolytic agents (e.g., aminocaproic acid, aprotinin, tranexamic acid) are coadministered with other hemostatic agents such as factor VIII inhibitor bypassing fraction, factor IX complex, prothrombin complex, or direct oral anticoagulant reversal agents.

MANAGEMENT: Concomitant administration of antifibrinolytic agents with other hemostatic agents should generally be avoided. Consult the manufacturer's product labeling for recommended dosing intervals between products.

References (4)
  1. (2001) "Product Information. Amicar (aminocaproic acid)." Immunex Corporation
  2. (2001) "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn
  3. (2022) "Product Information. Lysteda (tranexamic acid)." Xanodyne Pharmaceuticals Inc
  4. (2023) "Product Information. Tranexamic Acid (tranexamic acid)." Armas Pharmaceuticals, Inc.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer